Quantcast
Last updated on April 24, 2014 at 14:17 EDT

Latest aortic aneurysm Stories

2010-08-16 10:30:00

IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has entered into a development agreement and exclusive license with Evasc Medical Systems Corp., for its balloon expandable stent technology. Evasc is a medical device development company located in Vancouver, B.C. The patented stent is made from cobalt chromium and is pre-mounted on an angioplasty balloon catheter for...

2010-08-11 15:10:00

IRVINE, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, responded to the Bard Peripheral Vascular, Inc. lawsuit filed against Endologix in the United States District Court of Arizona. The Bard Peripheral lawsuit alleges that Endologix's proprietary high density ePTFE graft material, which is used for the Powerlink® System, infringes on Bard Peripheral's "Prosthetic Vascular...

2010-07-29 11:54:00

IRVINE, Calif., July 29 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its new PowerFit(TM) Aortic Extensions. The PowerFit extensions are designed to provide physicians with enhanced visibility under fluoroscopy to facilitate precise device placement during completion of the Anatomical Fixation endovascular repair of abdominal...

2010-07-13 15:30:00

IRVINE, Calif., July 13 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its second quarter 2010 financial results, which will take place on Thursday, July 22, 2010 after the close of the market. Endologix will hold a conference call on Thursday, July 22, 2010 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic...

2010-07-12 05:45:00

REYKJAVIK, Iceland, July 12, 2010 /PRNewswire-FirstCall/ -- Points to Novel Pathway for Drug Discovery, Will be Incorporated Into Tests to Improve Screening and Early Detection of Abdominal Aortic Aneurysm, Heart Attack and PAD Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a...

2010-07-06 11:00:00

IRVINE, Calif., July 6 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has appointed Todd Abraham to the newly created position of Vice President of Operations. Mr. Abraham will be responsible for managing all of Endologix's day-to-day operations and will report to John McDermott, President and Chief Executive Officer. Mr. McDermott, said, "Todd Abraham is a 25 year veteran of the medical...

2010-06-10 08:00:00

IRVINE, Calif., June 10 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable...

2010-06-07 12:04:00

BOSTON, June 7 /PRNewswire/ -- Patients with abdominal aortic aneurysms (AAAs) of less than 5.5 cm have no significant differences in clinical outcomes after endovascular repair (EVAR) than those with larger AAAs according to data from a five-year prospective clinical trial setting. The researchers maintain their recommendation that small aneurysms should not be treated surgically. Details of this study were presented at the 64th Vascular Annual Meeting presented by the Society for...

2010-06-04 08:00:00

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica High-Tech Innovation Awards on June 2, 2010 in Irvine, CA. John McDermott, President and CEO, said, "It is an honor to receive this award from TechAmerica. It is a...

2010-06-01 15:30:00

IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference in New York, NY. Jefferies 2010 Global Life Sciences Event: Conference Date: Wednesday, June 9, 2010 Time:...